

Santiago Rivera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/789237/publications.pdf>

Version: 2024-02-01

31
papers

1,781
citations

304743

22
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

2633
citing authors

#	ARTICLE	IF	CITATIONS
1	MT5-MMP promotes neuroinflammation, neuronal excitability and A β production in primary neuron/astrocyte cultures from the 5xFAD mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2022, 19, 65.	7.2	9
2	MT5-MMP controls APP and τ -CTF/C99 metabolism through proteolytic-dependent and -independent mechanisms relevant for Alzheimer's disease. <i>FASEB Journal</i> , 2021, 35, e21727.	0.5	6
3	Deficiency in MT5-MMP Supports Branching of Human iPSCs-Derived Neurons and Reduces Expression of GLAST/S100 in iPSCs-Derived Astrocytes. <i>Cells</i> , 2021, 10, 1705.	4.1	2
4	Donecopride, a Swiss army knife with potential against Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2020, 177, 1988-2005.	5.4	19
5	Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10705-10725.	6.4	42
6	Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer's Disease Pathogenesis in a Transgenic Mouse Model. <i>Neurotherapeutics</i> , 2019, 16, 1237-1254.	4.4	9
7	Emerging Alternative Proteinases in APP Metabolism and Alzheimer's Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 244.	3.4	46
8	Metalloproteinases in nervous system function and pathology: introduction. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3051-3053.	5.4	9
9	Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3167-3191.	5.4	73
10	Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking. <i>FASEB Journal</i> , 2019, 33, 2910-2927.	0.5	25
11	Chronic treatments with a 5-HT 4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2017, 126, 128-141.	4.1	41
12	Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer's disease: Alleviation by pantethine. <i>PLoS ONE</i> , 2017, 12, e0175369.	2.5	37
13	MT5-MMP, just a new APP processing proteinase in Alzheimer's disease?. <i>Journal of Neuroinflammation</i> , 2016, 13, 167.	7.2	26
14	Cerebrovascular pathology during the progression of experimental Alzheimer's disease. <i>Neurobiology of Disease</i> , 2016, 88, 107-117.	4.4	107
15	MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 217-236.	5.4	96
16	MT5-MMP Promotes Alzheimer's Pathogenesis in the Frontal Cortex of 5xFAD Mice and APP Trafficking in vitro. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 163.	2.9	34
17	Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer's disease: evidence for a pro-amyloidogenic role of MT1-MMP. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 247.	3.4	60
18	Endogenous and synthetic MMP inhibitors in CNS physiopathology. <i>Progress in Brain Research</i> , 2014, 214, 313-351.	1.4	39

#	ARTICLE	IF	CITATIONS
19	Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 33.	10.8	138
20	Onset of hippocampus-dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer's disease. <i>Hippocampus</i> , 2014, 24, 762-772.	1.9	89
21	Role of Matrix Metalloproteinases in Migration and Neurotrophic Properties of Nasal Olfactory Stem and Ensheathing Cells. <i>Cell Transplantation</i> , 2013, 22, 993-1010.	2.5	41
22	Evidence for Early Cognitive Impairment Related to Frontal Cortex in the 5XFAD Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 781-796.	2.6	79
23	Area-Specific Alterations of Synaptic Plasticity in the 5XFAD Mouse Model of Alzheimer's Disease: Dissociation between Somatosensory Cortex and Hippocampus. <i>PLoS ONE</i> , 2013, 8, e74667.	2.5	78
24	Trafficking and secretion of matrix metalloproteinase-2 in olfactory ensheathing glial cells: A role in cell migration?. <i>Glia</i> , 2011, 59, 750-770.	4.9	40
25	Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes. <i>Glia</i> , 2010, 58, 344-366.	4.9	105
26	Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology?. <i>Journal of Neuroscience</i> , 2010, 30, 15337-15357.	3.6	204
27	A New Role for TIMP-1 in Modulating Neurite Outgrowth and Morphology of Cortical Neurons. <i>PLoS ONE</i> , 2009, 4, e8289.	2.5	49
28	Neurogenesis in gerbil hippocampus following brain ischemia: focus on the involvement of metalloproteinases. <i>Acta Neurobiologiae Experimentalis</i> , 2009, 69, 52-61.	0.7	9
29	Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells. <i>Molecular and Cellular Neurosciences</i> , 2008, 39, 549-568.	2.2	84
30	Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an in vitro study. <i>BMC Neuroscience</i> , 2005, 6, 68.	1.9	24
31	Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. <i>European Journal of Neuroscience</i> , 2003, 18, 1507-1517.	2.6	161